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Vitamin D Depletion Aggravates Hypertension and Target-Organ
Damage
Louise Bjørkholt Andersen, MD; Lukasz Przybyl, MSc; Nadine Haase, PhD; Frauke von Versen-H€oynck, MD; Fatimunnisa Qadri, PhD;
Jan Stener Jørgensen, PhD; Grith Lykke Sorensen, PhD; Palle Fruekilde, MSc; Marko Poglitsch, PhD; Istvan Szijarto, PhD;
Maik Gollasch, PhD; Joerg Peters, MD; Dominik N. Muller, PhD; Henrik Thybo Christesen, PhD;* Ralf Dechend, MD*
Background-—We tested the controversial hypothesis that vitamin D depletion aggravates hypertension and target-organ damage
by inﬂuencing renin.
Methods and Results-—Four-week-old double-transgenic rats (dTGR) with excess angiotensin (Ang) II production due to
overexpression of the human renin (hREN) and angiotensinogen (hAGT) genes received vitamin D-depleted (n=18) or standard chow
(n=15) for 3 weeks. The depleted group had very low serum 25-hydroxyvitamin D levels (meanSEM; 3.80.29 versus
40.61.19 nmol/L) and had higher mean systolic BP at week 5 (1583.5 versus 134.63.7 mm Hg, P<0.001), week 6 (176.63.3
versus 162.33.8 mm Hg, P<0.01), and week 7 (171.65.1 versus 155.94.3 mm Hg, P<0.05). Vitamin D depletion led to
increased relative heart weights and increased serum creatinine concentrations. Furthermore, the mRNAs of natriuretic peptides,
neutrophil gelatinase-associated lipocalin, hREN, and rRenwere increased by vitamin D depletion. Regulatory T cells in the spleen and
in the circulation were not affected. Ang metabolites, including Ang II and the counter-regulatory breakdown product Ang 1 to 7, were
signiﬁcantly up-regulated in the vitamin D-depleted groups, while ACE-1 and ACE-2 activities were not affected.
Conclusions-—Short-term severe vitamin D depletion aggravated hypertension and target-organ damage in dTGR. Our data suggest
that even short-term severe vitamin D deﬁciency may directly promote hypertension and impacts on renin-angiotensin system
components that could contribute to target-organ damage. The ﬁndings add to the evidence that vitamin D deﬁciency could also
affect human hypertension. ( J Am Heart Assoc. 2015;4:e001417 doi: 10.1161/JAHA.114.001417)
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V itamin D deﬁciency or insufﬁciency, deﬁned as serum25-hydroxyvitamin D levels (25(OH)D) <50 nmol/L, is common worldwide.
1 Vitamin D3 supplementation reduced
the risk of all-cause and cancer mortality in a recent Cochrane
analysis.2 Other extra-skeletal effects of vitamin D deﬁciency
or insufﬁciency are possible but not ﬁrmly established since
the threshold of such effects may vary.3 Several large
observational studies linked low 25(OH)D levels to all-cause
mortality and cardiovascular events, including hypertension,4–6
and systolic blood pressure (BP).7,8 A recent large meta-
analysis suggested that a 25 nmol/L increase in 25(OH)D
levels lowers the risk of incident hypertension by 12%.9
However, these studies did not clarify causality. Vitamin D
status could merely be a marker of lifestyle or environment.
The vitamin D receptor and 1-alpha-hydroxylase are
expressed in all cardiovascular tissues. Several protective
mechanisms have been suggested, such as down regulation
of pro-inﬂammatory cytokines and regulatory T cells.10–12 The
most notable hypothesis linking vitamin D to BP is its
potential role as an inverse endocrine regulator of the renin-
angiotensin system (RAS). In animal studies, vitamin D3 acted
as a down regulator of renin.13 Furthermore, vitamin D is
involved in transcriptional repression of renin expression
through a cyclic-AMP response element in the renin gene
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promoter.14 Finally, vitamin D receptor knockout mice had
signiﬁcantly elevated renin and angiotensin (Ang) II concen-
trations. The mice also developed hypertension and target-
organ-damage.15 In human cross-sectional studies, lower
vitamin D levels were associated with higher plasma renin
activity (PRA), higher Ang II concentrations, altered responses
to Ang II, and higher RAS activity in vascular tissue.16–20 Little
is known about the effect of vitamin D on other RAS
components, particularly metabolites of angiotensinogen. Ang
1 to 7 appears to counteract the actions of Ang II.21 We
performed studies in double-transgenic rats expression
human renin (hREN) and angiotensinogen (hAGT) to investi-
gate an interaction between vitamin D deﬁciency and the
human RAS in a rat model.
Methods
We purchased dTGR rats (n=33) and non-transgenic control
Sprague-Dawley rats (n=12) from Harlan A/S. Our local
review board (State Ofﬁce of Health and Social Affairs
[LAGeSo], permit number G160/09) approved the studies
that complied with guidelines from the American Physiology
Society. Age-matched male dTGR and non-transgenic Spra-
gue-Dawley rats at weaning (age 4 weeks) were given free
access to drinking water and either a vitamin D-deﬁcient diet
with normal calcium and phosphorus, or a diet with normal
vitamin D amounts (AIN93G; SSNIFF, Germany). Systolic BP
was measured under light anesthesia weekly by tail-cuff. The
“Tail cuff” apparatus was built by the workshop of our
institute. Light anesthesia was employed to ensure correct
and safe handling of the rats during the procedure. The
animals were placed in metabolic cages once weekly, and 24-
hour urine albumin excretion (ELISA; CellTrend) was mea-
sured. Rats were killed by guillotine at age 7 weeks, after light
ether anesthesia to ensure safe and correct handling. Blood
for hormone analysis was drawn by aortic puncture into pre-
chilled tubes containing EDTA (6.25 mmol/L) and phenan-
throline (26 mmol/L) as anticoagulant and inhibitor of Ang II
breakdown in vitro, respectively. Serum was collected for
further analysis. The heart, liver, and kidneys were washed
with ice-cold saline, blotted dry, and weighed. For Western
blot, and RT-PCR analysis, the tissues were snap-frozen in
liquid nitrogen, for immunohistochemistry in isopentane
(35°C), and stored at 80°C.
Total cardiac and kidney RNA was isolated with TRIZOL
followed by the Qiagen protocol, and TaqMan reverse-
transcription polymerase chain reaction was performed as
recommended by the manufacturer. The sequences of the
primers are described earlier.22,23 Quantitative analysis of
target mRNA expression was performed with real-time PCR
using the relative standard curve method. GAPDH or 18S were
chosen as the endogenous control (“housekeeping gene”).
The expression level of the target genes ANP and BNP in the
heart was normalized by GAPDH. The expression level of the
target genes neutrophil gelatinase-associated lipocalin (N-
GAL), hREN, rRen, hAGT, and rAgt in the kidney was
normalized by 18S.
Techniques for measuring plasma renin activity (PRA),
plasma renin concentrations (PRC), and Ang I generation are
outlined in detail elsewhere.24 We used mass spectrometry to
investigate the effect of vitamin D depletion on Ang metab-
olites. This technique allows for measurement of 10 metab-
olites, including Ang 1 to 10 (Ang I), Ang 1 to 8 (Ang II), Ang 1
to 7 (MAS receptor agonist), Ang 2 to 8 (Ang III) and Ang 3 to
8 (Ang IV). Plasma samples were spiked with 100 pg/mL
stable-isotope-labeled internal standards and subjected to
solid-phase extraction using Sep-Pak cartridges (Waters)
according to manufacturer’s protocol. Following elution and
solvent evaporation, samples were reconstituted in 50 lL
50% acetonitrile/0.1% formic acid and subjected to LC-MS/
MS analysis using a reversed-phase analytical column (Luna
C18, Phenomenex) using a gradient ranging from 10%
acetonitrile/0.1% formic acid to 70% acetonitrile/0.1% formic
acid in 9 minutes. The eluate was analyzed in line with a
QTRAP-4000 mass spectrometer (AB Sciex) operated in the
MRM mode using dwell times of 25 msec at a cone voltage of
4000 volts and a source temperature of 300°C. For each
peptide and corresponding internal standards, 2 different
mass transitions were measured. Ang peptide concentrations
were calculated by relating endogenous peptide signals to
internal standard signals provided that integrated signals
achieved a signal-to-noise ratio above 10. We calculated ACE1
and ACE2 activity according to the established ratio; ACE-1
activity was estimated as Ang II/Ang 1 to 10 and ACE-2
activity was estimated as Ang 1 to 7/Ang 1 to 8. For vitamin
D determinations, serum was stored at 20°C until analysis,
which was performed as previously reported for human
serum.25 Brieﬂy, vitamin D2 and D3 were measured as
individual components in one single analysis on a TurboFlow
LC-MS/MS system (TLX2 HPLC with a Vantage TSQ MS, all
from Thermo Scientiﬁc). For internal standard, d3-25-OH-
vitamin D3 (Sigma-Aldrich) was used. Calibration curves were
veriﬁed with NIST 972 and 2972.
Spleens and heparinized blood for analysis of regulatory T
cells were collected from dTGR in the 2 groups (depletion and
control) at the time of death. Tissues were minced through
70 lm sieves and washed with cold PBS containing 0.1% FCS.
Flow-through and blood were subjected to osmotic lysis of red
blood cells at 37°C. Next, cell suspension was ﬁltered through
40 lm sieves, diluted and centrifuged at 300g for 10 min-
utes, at 4°C. Cells were then washed twice using cold PBS/
FCS buffer. Cells in single-cell suspension were stained with
anti-CD4, anti-CD25, and permeabilized and stained with anti-
FoxP3 (FoxP3 kit from BioLegend, San Diego, CA, CD4-FITC
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[clone: OX-35] [#554837; BD Biosciences] and CD25-PE
[clone: OX-39] [#554866; BD Biosciences]). All analyses,
including isotype control, were gated for CD4+ cells. Flow
cytometry was performed with FACSDiva software (BD
Biosciences, San Jose, CA). Data were analyzed with FlowJo
software (Tree Star, Ashland, OR).
Data are presented as meanstandard error (SEM). Data
were tested for normality using the D’Agostino-Pearson
omnibus test, and if it did not satisfy normality, data were
log-transformed. Statistical signiﬁcance of the differences in
mean values was tested by unpaired T tests. We accepted
P<0.05 as signiﬁcant. We tested for equality of variance using
the F test. If a difference in variance was found, the t test was
used with Welch’s correction for unequal standard deviations.
Data were analyzed with GraphPad Prism software (GraphPad
Software, La Jolla, CA).
Results
After 3 weeks, the group receiving vitamin D-depleted chow
(VDd-dTGR) had very low serum 25(OH)D3 levels of
80.7 nmol/L, whereas the controls (ctl-dTGR) had levels
of 40.62.9 nmol/L (Figure 1A). None of the groups had
detectable levels of 25(OH)D2. Systolic BP was higher in the
VDd-dTGR group relative to ctl-dTGR throughout the study.
Already at week 5, VDd-dTGR had higher systolic BP at
1583.5 versus 134.63.7 mm Hg, P<0.001, week 6
176.63.3 versus 162.33.8 mm Hg, P<0.01, and week 7
171.65.1 versus 155.94.3 mm Hg, P<0.05 (Figure 1B).
Both depleted and control dTGR displayed substantial
cardiac hypertrophy. Log-transformed relative heart weight
was signiﬁcantly higher for VDd-dTGR (0.750.01 versus
0.710.01 mg/g, P<0.01) (Figure 2A). Relative expression of
markers of heart failure were signiﬁcantly higher in heart
tissue from the depletion group, atrial natriuretic peptide
(ANP) at 0.800.06 versus 0.600.05 arbitrary units (AU),
P<0.05 and brain natriuretic peptide (BNP) at 0.830.06
versus 0.570.07 AU, P<0.01 (Figure 2B). Albuminuria was
present in both groups, but did not differ signiﬁcantly at any
time point (Figure 3A). The VDd-dTGR group exhibited
substantially higher relative mRNA expression of neutrophil
gelatinase-associated lipocalin (N-GAL) in kidney tissue than
the ctl-dTGR, at 2.100.3 versus 1.300.15 AU, P<0.05
(Figure 3B), and higher plasma creatinine levels at
22.430.48 versus 18.830.87 lmol/mL, P<0.01 as well
as a tendency towards higher plasma cystatin C levels at
2260146 versus 1929110 ng/mL, P=0.1. Tissue analyses
for inﬂammation and ﬁbrosis by immunohistochemistry
showed no difference between depleted and control dTGR in
heart and kidney tissue (Figures 4 and 5). Vitamin D depletion
in non-transgenic Sprague-Dawley rats had no effect on blood
pressure, proteinuria, GFR, absolute and relative heart weight,
renal N-GAL, and cardiac BNP expression, compared with
control rats with normal diet (data not shown). We did not
observe an effect on renal rRenin and liver rAogen expression
by vitamin D depletion (data not shown).
To investigate the vitamin D-mediated molecular mecha-
nism, we investigated whether the RAS was induced by
vitamin D depletion. Analysis of mRNA showed that both
human and rat renin were up-regulated in the VDd-dTGR
compared to ctl-dTGR, human renin at 1.810.33 versus
0.890.13 AU, P<0.05 and rat renin at 1.160.14 versus
0.770.08 AU, P<0.05 (Figure 6A). Liver tissue was exam-
ined for relative mRNA expression of human and rat
angiotensinogen, however there were no signiﬁcant differ-
ences in expression between VDd-dTGR and ctl-dTGR (Fig-
ure 6B).
PRC and PRA were increased in VDd-dTGR (Table 1).
Similarly, Ang I generation was signiﬁcantly higher in the
circulation of VDd-dTGR compared with controls. Nine of 10
angiotensin metabolites (Table 2) were signiﬁcantly up-regu-
lated in the VDd-dTGR group, including Ang II and Ang 1 to 7.
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Figure 1. Serum 25(OH)D3 concentration and systolic blood pressure. A, Vitamin D-depleted rats had a
signiﬁcant decrease in serum 25-hydroxyvitamin D3 after 3 weeks on vitamin D-depleted chow. Results are
expressed as meanSEM of at least 6 animals per group. B, Systolic BP increased progressively in vehicle-
treated dTGR from week 5 to week 7. Vitamin D depletion increased BP from week 5 to 7. BP indicates
blood pressure; ctl-dTGR, controls double-transgenic rats; VDd, vitamin D-depleted.
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Moreover, ACE-1 activity (estimated as Ang II/Ang 1 to 10)
and ACE-2 activity (estimated as Ang 1 to 7/Ang 1 to 8) were
not different between the 2 groups. Because vitamin D is
known to induce regulatory T cells, we investigated whether
or not vitamin D deﬁciency would affect regulatory T cells
(CD4+CD25+FoxP3). No difference in the spleen or in
peripheral blood was found (Figure 7).
Discussion
We found that short-term dietary depletion of vitamin D
aggravated both hypertension and cardiovascular target-organ
damage in dTGR rats. We attribute these effects to up-
regulation of both the hREN transgene and the endogenous
rRen in the VDd-dTGR group, leading to increased generation
of various angiotensin peptides, after only 3 weeks of vitamin
D depletion. However, neither hATG or rAgt expression nor
ACE-1 nor ACE-2 activity were altered by vitamin D depletion.
Moreover, vitamin D depletion did not alter the relative
percentages of regulatory T cells, suggesting that regulatory
T-cell deﬁciency was not responsible for the higher BP and
target-organ damage.
Several rodent studies have been conducted to investi-
gate the effect of vitamin D supplementation on hyperten-
sion and target-organ damage, using the Dahl salt-sensitive
rats26–28 and models of renal failure and nephropathy.29–31
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Figure 2. Effect of vitamin D depletion on cardiac hypertrophy, BNP, and ANP expression. Vitamin D
depletion-induced cardiac hypertrophy (A) expressed as ratio of heart weight to body weight. Cardiac
hypertrophy indices of VDd-dTGR were signiﬁcantly higher compared with ctl-dTGR. B, With RT-PCR, we
examined BNP (left) and ANP (right) mRNA expression in the heart. ANP and BNP mRNA expression were
signiﬁcantly higher in VDd-dTGR compared with ctl-dTGR. mRNA levels of BNP and ANP were normalized for
the housekeeping gene GAPDH. Results are expressed as arbitrary units (AU) with meanSEM of at least 7
animals per group. ANP indicates atrial natriuretic peptide; BNP, brain natriuretic peptide; ctl-dTGR, controls
double-transgenic rats; RT-PCR, real-time polymerase chain reaction; VDd, vitamin D-depleted.
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Figure 3. Effect of vitamin D depletion on renal function. A, dTGR developed progressive increased 24 hours urinary albumin excretion, which
was not changed by vitamin D depletion. B, Left to right: Plasma creatinine was signiﬁcantly higher in VDd-dTGR. Serum cystatin C concentration
was higher in VDd-dTGR, but this was only a trend (P=0.1). The expression of NGAL mRNA kidney tissue was signiﬁcantly higher in VDd-dTGR
compared with ctl-dTGR. mRNA levels of NGAL were normalized for the housekeeping gene 18S. Results are expressed as arbitrary units (AU)
with meanSEM of at least 7 animals per group. ctl-dTGR indicates controls double-transgenic rats; VDd, vitamin D-depleted.
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Figure 4. A and B, Masson Goldner staining for ﬁbrosis in formalin ﬁxed parafﬁn-embedded kidney
sections (top: lower magniﬁcation, middle: higher magniﬁcation). C, Macrophage immunoﬂuorescent
staining (ED1) in formalin-ﬁxed parafﬁn-embedded Kidney Sections and quantiﬁcation of ED1-positive Cells.
All measurements were performed in double transgenic rats with normal diet (VDs-dTGR) and after vitamin
D depletion (VDd-dTGR). dTGR indicates double-transgenic rats; VDd, vitamin D-depleted.
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Figure 5. A and B, Picro Sirius Red staining for ﬁbrosis in formalin ﬁxed parafﬁn-embedded heart Sections
(top: lower magniﬁcation, middle: higher magniﬁcation). Quantiﬁcation of Fibrosis in Picro Sirius Red staining (C)
Immunoﬂuoresence staining of macrophages (ED1) in formalin-ﬁxed parafﬁn-embedded heart sections and
quantiﬁcation (% Area Measured as Area related to whole LV). All measurements were performed in double
transgenic rats with normal diet (VDs-dTGR) and after vitamin D depletion (VDd-dTGR). dTGR indicates double-
transgenic rats; LV, left ventricule; VDd, vitamin D-depleted.
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Most of these studies found an ameliorating effect. Li et al
showed that vitamin D-receptor deletion in mice leads to
up-regulation of both rodent renin mRNA and protein
expression in the kidney.15 These mice had elevated renin
and Ang II concentration, as well as hypertension and
target-organ damage.15 Furthermore, 1,25–dihydroxyvitamin
D3 (1,25(OH)2D3), is involved in transcriptional repression of
renin expression, through a cyclic AMP response element in
the renin gene promoter.14 A mouse model of 1a-hydrox-
ylase-gene deletion showed that the enzyme protects the
cardiovascular system by suppressing the RAS.32 Six-week
vitamin D depletion in LDL-receptor and apolipoprotein E-
null mice resulted in reversible increases in systolic and
diastolic BP with elevated plasma renin.33 The null mice
develop substantial renal and cardiovascular target-organ
damage compared to controls. The induction of renin is
independent of calcium and parathyroid hormone34 and is a
direct effect of altered 1,25(OH)2D3 levels. In juxtaglomer-
ular cells 1,25(OH)2D3 directly suppressed renin gene
transcription, which was dependent on the vitamin D
receptor. Treatment of juxtaglomerular cells with 1,25
(OH)2D3 decreased promoter activity of a transfected
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Figure 6. Renin and angiotensinogen expression. A, Vitamin D depletion resulted in a signiﬁcant increase
in mRNA expression of human renin (left) and rat renin (right) in the kidney. B, mRNA expression of human
angiotensinogen (left) and rat angiotensinogen (right) were similar between VDd- and ctl-dTGR. mRNA levels
of the target genes were normalized for the housekeeping gene 18S. Results are expressed as arbitrary
units (AU) with meanSEM of at least 7 animals per group. ctl-dTGR indicates controls double-transgenic
rats; hAGT, human angiotensinogen; VDd, vitamin D-depleted.
Table 1. Plasma Renin Concentration and Activity (MeanSEM)
ctl-dTGR VDd-dTGR P Value
PRC (sheep substrate) ng Ang I/(mL per h) 16.457.3 26.5812.5 0.05
PRC (rat substrate) ng Ang I/(mL per h) 11.473.4 23.299.1 0.01
PRA ng Ang I/(mL per h) 35.7935.81 54.2238.8 0.34
Ang I ng/mL 4.981.6 8.582.5 0.01
Ang I indicates angiotensin I; ctl-dTGR, controls double-transgenic rats; PRA, plasma renin activity; PRC, plasma renin concentration; VDd, vitamin D-depleted.
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reporter construct, containing the same ﬂanking sequences
as used in our dTGR.35 The molecular mechanism of the
vitamin D induced renin down-regulation is only partially
understood. 1,25(OH)2D3 blocks the formation of the cyclic
AMP response element-binding protein (CREB) and the
related partner complex.14 Furthermore, the transcriptional
regulatory complex made up of CREB1, nuclear receptor co-
repressor 1 (NCOR1), and the vitamin D receptor, which
bind to the cyclic AMP response element-like domain in the
renin enhancer, are also important in the suppression of
renin.36
In infants, reversible cardiomyopathy has been reported in
infants with nutritional rickets, and simultaneously low
vitamin D and calcium levels.37,38 Furthermore, a recent
study of taketsubo-cardiomyopathy in adult women also
suggested an association to low vitamin D levels.39 Random-
ized clinical trials of vitamin D supplementation for reduction
of BP in humans are conﬂicting. A recent trial meta-analysis of
the effect of oral vitamin D supplementation on BP showed a
trend towards a reduction in diastolic BP and a small, but
signiﬁcant reduction in diastolic BP, in patients with preex-
isting cardiovascular risk.9 In a trial with hypertensive
patients, the group receiving vitamin D supplementation
showed a 4 mm Hg decrease in central systolic BP. In
patients with baseline 25OHD <80 nmol/L, a decrease in
both systolic and diastolic BP was observed.40 Others found a
signiﬁcant decrease in systolic BP with calcitriol intervention
in hypertensive patients41 or paricalcitol intervention in
diabetic patients.42 However, The Women’s Health Initiative
trial with vitamin D and calcium intervention, failed to show an
effect of vitamin D on BP or incident hypertension.43 Another
trial of chronic renal disease patients found no effect of
paricalcitol therapy on BP.44,45 Our study supports the idea
that profoundly low 25(OH)D levels may aggravate hyperten-
sion and adds mechanistic information. To our knowledge, no
studies have previously focused on the effect of short-term
vitamin D depletion in humans.
In earlier studies, we showed that both human and rat
renin mRNA were expressed in the kidneys of dTGR.46
However, the 2 renin mRNAs were decreased, indicating a
physiological down-regulation probably by high BP. Our
current experiments show that the up-regulation of rat renin
by vitamin D depletion is important and pronounced, since it
overcomes the expected down-regulation by high BP.46 We
observed an effect on BP after only 3 weeks of depletion,
which points towards a very rapid effect of vitamin D
depletion on hypertension. This ﬁnding is clinically interesting
as it suggests that the human renin-angiotensin axis may be
quite sensitive to changes in serum levels of 25(OH)D.
Vitamin D-binding protein and serum albumin both bind 25
(OH)D, and a measurement of the 2 binding proteins could
have enabled us to calculate the amounts of bioavailable 25
(OH)D in the rat circulations.47 However, in this study,
depletion of dTGR rats resulted in very low levels of vitamin D
(80.7 nmol/L versus 40.62.9 nmol/L) and it is reason-
able to assume that the proportion of bioavailable vitamin D
would be correspondingly very low, if not negligible. Calcu-
lation of the bioavailable fraction might be of more value in an
intervention study with supplementation, where it is of
interest to ﬁnd the increase in bioactive vitamin D. A further
limitation to our study is not using radiotelemetry for
measuring blood pressure. Yet, the tail cuff method has been
used by the group in research with this transgenic rodent
model for many years, and is reliable and reproducible,
Table 2. Angiotensin Metabolites in the Circulation, Measured By Mass Spectroscopy (MeanSEM)
Parameter (pg/mL) ctl-dTGR (MeanSEM) VDd-dTGR (MeanSEM P Value
Ang 1 to 5 5.00.0 6.10.3 <0.001
Ang 1 to 7 25.24.6 48.35.9 <0.01
Ang 1 to 8 748.335.0 1512.0180.3 <0.01
Ang 1 to 9 6.70.3 8.40.2 <0.001
Ang 1 to 10 918.677.9 1764.0223.0 <0.01
Ang 2 to 7 2.00.0 2.90.1 <0.0001
Ang 2 to 8 70.94.7 125.512.7 <0.01
Ang 2 to 10 21.94.1 41.18.9 0.074
Ang 3 to 7 2.10.1 3.00.0 <0.0001
Ang 3 to 8 42.32.5 88.410.5 <0.01
ACE2 Activity (Ang 1 to 7/Ang 1 to 8) 0.0350.007 0.0320.001 0.72
ACE1 Activity (Ang 1 to 8/Ang 1 to 10) 0.8510.079 0.8650.037 0.87
ACE indicates angiotensin converting enzyme; ANG, angiotensin; ctl-dTGR, controls double-transgenic rats; VDd, vitamin D-depleted.
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particularly seeing as the animals develop very high blood
pressures. However, radiotelemetry could have been more
accurate in this experimental setting.
Our group previously demonstrated that adoptive regula-
tory T-cell transfer could ameliorate angiotensin-II induced
target-organ damage.48 In addition, vitamin D has been shown
to regulate relative numbers and activity of regulatory T cells
in experimental and clinical studies.12,49 These observations
caused us to investigate regulatory T cells in the current
study. However, we did not ﬁnd any evidence that splenic or
peripheral numbers of regulatory T cells differed between
groups.
We also observed that the Ang ratios, indicating ACE-1 and
ACE-2, activity were not inﬂuenced by vitamin D depletion. We
determined the expression of rat and human renin and
angiotensinogen in liver and kidney and measured the
concentrations of Ang metabolites in the serum by mass
spectroscopy. Our ﬁndings lead us to conclude that the
differences induced by vitamin D depletion were based solely
on the up-regulation of renin expression and activity. The
induction of renin subsequently leads to a higher serum
concentration of Ang metabolites, while other enzymes of the
RAS were not induced by vitamin D depletion. Instead, we
observed a direct effect on the hREN transgene. Interestingly,
the hREN transgene harbors the human renin gene promoter
including all its ﬂanking regions,50 the proposed site of 1,25
(OH)2D3 action.
14
Conclusion
Blockade of the renin-angiotensin system with ACE inhibitors,
AT1 receptor blockers, or direct renin inhibitors, all increase
circulating renin. Conceivably, vitamin D supplementation or
substitution in severe vitamin D deﬁciency could blunt this
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Figure 7. Effect of vitamin D depletion on regulatory T-cells. A, Percentage of FoxP3+ cells, calculated
relative to CD4+ cells in spleen (left) and peripheral blood (right) are shown. Results are expressed with
meanSEM of at least 7 animals per group (spleen) or 3 animals per group (peripheral blood). Vitamin D
depletion did not alter regulatory T-cells compared to control dTGR. B, representative example of a FACS in
spleen and peripheral blood. ctl-dTGR indicates controls double-transgenic rats; VDd, vitamin D-depleted.
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increase. This hypothesis could be tested in subsequent
translational studies. Furthermore, by adding anti-hyperten-
sive drugs not targeting the RAS system to studies with dTGR
rats, the degree of non-hypertensive Ang II induced organ
damage could be established.
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